Peptides for sleep: the evidence grade

Peptides marketed for sleep and recovery divide into two very different bodies of evidence. One compound, MK-677 (ibutamoren), has a small but controlled human trial showing genuine improvements in sleep architecture. The rest, including ipamorelin and CJC-1295, rest on a plausible but indirect chain of reasoning: they raise growth hormone, GH secretion is linked to slow-wave sleep, therefore they might improve sleep. That chain has not been tested directly in humans in a controlled trial for either peptide. This article sets out what the published evidence actually shows.

The short version: the GH-sleep physiology is real and well-documented. Whether stimulating GH via a secretagogue translates to better sleep in humans is, for ipamorelin and CJC-1295, still a theoretical inference.

The GH-sleep connection: what the physiology says

The relationship between growth hormone secretion and sleep architecture is one of the better-established links in sleep endocrinology. Van Cauter and Plat (1996) reported that in men, approximately 70% of GH pulses during sleep coincide with slow-wave sleep (SWS), and the amount of GH secreted during those pulses correlates with the concurrent amount of SWS^[1]. The temporal relationship is bidirectional: GH release peaks at the first SWS episode of the night, and the depth of that slow-wave stage determines the size of the pulse.

Van Cauter, Leproult, and Plat (2000), in a JAMA paper covering 149 healthy men aged 16 to 83, showed that slow-wave sleep declines from about 19% of sleep in early adulthood to about 3% by mid-life, with a parallel fall in GH secretion of 372 micrograms per decade^[2]. GH secretion was significantly associated with slow-wave sleep independent of age.

The direction of causation is not settled, though. Jessup et al. (2004), in a randomised controlled trial in healthy men, blocked endogenous GHRH and found that the percentage of slow-wave sleep was unchanged compared to saline^[3]. GH secretion during sleep depends on GHRH, but GHRH does not appear to generate SWS. Raising GH via a secretagogue may not automatically deepen slow-wave sleep.

MK-677: the strongest human sleep data in this class

MK-677 (ibutamoren) is an oral, non-peptide GH secretagogue that mimics ghrelin at the GHS-R receptor. It is not approved as a medicine anywhere in our coverage area. The best sleep-specific data comes from a 1997 double-blind, placebo-controlled crossover trial by Copinschi and colleagues^[4].

What the trial found

Copinschi et al. (1997) administered MK-677 or placebo to 8 young adults (aged 18 to 30) and 6 older adults (aged 65 to 71). In the younger group, high-dose MK-677 produced an approximately 50% increase in stage IV sleep duration and more than a 20% increase in REM sleep^[4]. Sleep abnormalities decreased from 42% of nights under placebo to 8% under high-dose MK-677 (p less than 0.03). In older adults, high-dose MK-677 produced a nearly 50% increase in REM sleep and a decrease in REM latency.

What the trial does not tell us

Sample sizes were small (n=8 young, n=6 older). The trial was not designed to assess functional recovery outcomes. MK-677's mechanism also differs from injectable peptide secretagogues: it acts at the ghrelin receptor (GHS-R). Weikel et al. (2003) showed that ghrelin itself, administered intravenously to 7 participants, increased slow-wave sleep across the whole night^[5]. The MK-677 sleep signal may partly reflect its ghrelin-receptor activity rather than the GH elevation specifically.

Ipamorelin: GH secretion confirmed, sleep data absent

Ipamorelin is a selective synthetic pentapeptide GH secretagogue. Unlike older GH-releasing peptides such as GHRP-2 or GHRP-6, ipamorelin does not significantly raise cortisol or prolactin in preclinical work. The only published human study is Gobburu et al. (1999), which characterised GH stimulation in healthy men at five dose levels^[6]. GH release peaked at approximately 0.67 hours. The study confirmed GH stimulation but was not designed to examine sleep, and there is no published randomised trial of ipamorelin measuring sleep outcomes.

The community case for ipamorelin improving sleep rests on the GH-SWS relationship documented by Van Cauter and colleagues^[1]: indirect reasoning rather than a direct test. Ipamorelin is not approved as a medicine anywhere we cover and is WADA-prohibited under S2.

CJC-1295: GH elevation confirmed, sleep not studied

CJC-1295 is a modified 30-amino-acid GHRH analogue with a half-life of roughly five to eight days. Two small Phase I studies form the human evidence base. Teichman et al. (2006) found a single injection produced a two- to tenfold GH increase lasting six days or more^[7]. Ionescu and Frohman (2006) found CJC-1295 increased mean GH secretion by 46% and IGF-I by 45% while preserving pulsatile GH release^[8]. Neither trial measured sleep. The ConjuChem programme stalled after 2006; no Phase 2 or 3 trial has been completed. See the CJC-1295 regulation pages for per-country status: no marketing authorisation exists anywhere and the compound is WADA-prohibited under S2.

How the evidence grades out

MK-677 has the strongest sleep-specific evidence in this class: a controlled crossover trial with polysomnographic measurement in humans^[4]. Small sample sizes, no approved status, and a GHS-R mechanism that complicates interpretation for injectable secretagogues. Ipamorelin has GH secretion confirmed in one human PK/PD study^[6] but no sleep outcome data. CJC-1295 has GH elevation confirmed in two small Phase I trials^[7][8] and no sleep outcome data. For both ipamorelin and CJC-1295, the evidence for sleep improvement is indirect class-level reasoning rather than compound-specific trial results.

What we don't yet know

Two questions remain open. First, whether the MK-677 sleep findings replicate in larger trials with recovery-specific endpoints beyond polysomnography. The n=14 from Copinschi et al. is too small to build clinical decisions on, and no follow-up trial has been published. Second, whether augmenting GH via a GHRH analogue or GHRP-type secretagogue actually deepens slow-wave sleep: the Jessup et al. result that blocking GHRH did not reduce SWS raises the possibility that GH secretion and SWS are more loosely coupled than the Van Cauter association data suggest. If so, the indirect reasoning behind ipamorelin and CJC-1295 for sleep is weaker than the community discussion implies.

The sleep-recovery primer on this site covers what users report and what typical protocols look like. This article covers the controlled evidence. The two are intended to be read together. For compound-specific information, see the ipamorelin peptide page and the CJC-1295 peptide page.

This article is for educational and research purposes only. It does not constitute medical advice. Any decision about whether to use any of the compounds discussed belongs with a qualified healthcare professional who knows your individual history. Compounds discussed here may be classified as unauthorised medicines, research chemicals, or prohibited substances depending on your jurisdiction.